An Introduction to Dissemination of Information about Unapproved Uses for Medical Product Advertising and Promotion

A session from FDLI’s Introduction to Advertising and Promotion for Medical Products
Recorded October 16, 2024

An Introduction to Dissemination of Information about Unapproved Uses for Medical Product Advertising and Promotion

Explore crucial aspects of topics such as unapproved use and intended use, and the First Amendment legal decisions underlying these concepts. Discuss guidance documents FDA has issued on this topic, as well as special circumstances regarding dissemination of use information.

Why It Matters and What It Means

  • First Amendment Jurisprudence: Central Hudson, Washington Legal Foundation v. Henney, Caronia, and Other Key Decisions
  • Key Concepts: Intended Use, Unapproved Use, and Practice of Medicine
  • FDA Final Guidance: Drug and Device Manufacturer Communications with Payors, Formulary Committees, and Similar Entities – Questions and Answers
  • FDA Final Guidance: Medical Product Communications that are Consistent with the FDA-Required Labeling – Questions and Answers
  • Good Reprint Practices
  • Scientific and Educational Activities, Including Continuing Education
  • Role of Medical Science Liaisons (MSLs); Unsolicited Requests for Information by Medical Professionals

Dominick Paul DiSabatino, Attorney, Sheppard Mullin Richter & Hampton LLP, FDLI Curriculum Advisor

This session was recorded as part of FDLI’s Introduction to Advertising and Promotion for Medical Products Course in October 2024.

Get Access

$149
  • +$100 for nonmembers

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.

 

On-demand content can be played back on most devices.

 

CLE credit is not currently available for pre-recorded sessions.

Related Content